BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES (Tables)

3 Months Ended

Dec. 31, 2022

BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES

Schedule of revenues disaggregated by business operations and timing of revenue recognition

The following table presents revenues disaggregated by our business operations and timing of revenue recognition:

	Three Month Period Ended:
	December 31,		December 31,
	2022		2021
Research and development services (over-time)	$	126,058	$	105,695
Clinical laboratory testing services (point-in-time)		3,074,414		1,873,722
Clinical laboratory testing services (over-time)		1,439,881		1,326,400
Product and authentication services (point-in-time):
Supply chain		411,765		411,547
Large Scale DNA Production		127,506		—
Asset marking		83,128		105,522
MDx test kits and supplies		—		342,820
Total	$	5,262,752	$	4,165,706

Schedule of opening and closing contract balances

The opening and closing balances of the Company’s contract balances are as follows:

		October 1,		December 31,		$
	Balance sheet classification	2022		2022		change
Contract liabilities	Deferred revenue	$	563,557	$	273,880	$	289,677

Schedule of anti-dilutive securities not included computation of net loss per share

	2022	2021
Warrants	7,295,588	743,563
Stock options	1,006,141	1,061,460
Total	8,301,729	1,805,023